1 minute read
Jan. 17, 2022
MRTX1133: A First-in-Class Oral KRAS(G12D) Inhibitor
MRTX1133
reversible KRASG12D inhibitor preclinical efficacy in cancer model from SBDD around KRASG12C inhibitor Journal of Medicinal Chemistry Mirati Therapeutics, San Diego, CA
Reviewer:
Loading...
